TrialBMC medicine2022

Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.

Jonathan F Lovell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.